Invega Sustenna (Paliperidone Palmitate) Patent Expiration, LOE Window & CMS Spending

Invega Sustenna (Paliperidone Palmitate) by Johnson & Johnson: FDA Orange Book LOE 2031-01-26, 11 AB generics, $3.64B 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN022264 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-01-26
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors11
2024 CMS Total Public Spend$3.64B
2024 Medicare Part D Spend$1.88B
2024 Medicaid Spend$1.76B
Reported Wholesale Price Change (CA SB 17)10 WAC filings (max 19.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.